Algorae Pharmaceuticals Ltd (ASX:1AI) Share Price

Company Profile

Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUS
T: +61 422180317
https://www.algoraepharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
48

Recommended

Current operating conditions are challenging but over the long-term prospects are better.

Johannes Faul | 25 February 2025

Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.

Joseph Taylor | 25 February 2025

Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.

Morningstar | 25 February 2025

Index	Last price	Change	% Change
All Ordinaries	8,477.30	20.70	-0.24%
CAC 40	8,141.19	90.12	1.12%
DAX 40	22,790.56	380.29	1.70%
Dow JONES (US)	43,810.49	189.33	0.43%
FTSE 100	8,732.37	63.70	0.73%
HKSE	23,787.93	753.91	3.27%
NASDAQ	19,269.50	243.11	1.28%
Nikkei 225	38,142.37	95.42	-0.25%
NZX 50 Index	12,452.46	145.19	1.18%
S&P 500	6,007.46	52.21	0.88%
S&P/ASX 200	8,240.70	11.20	-0.14%
SSE Composite Index	3,380.21	34.17	1.02%